RGD Reference Report - Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Effect of Chemotherapy in an Animal Model of Regional Therapy for the Treatment of Advanced Extremity Malignant Melanoma. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Inhibition of Poly(ADP-Ribose) Polymerase Enhances the Effect of Chemotherapy in an Animal Model of Regional Therapy for the Treatment of Advanced Extremity Malignant Melanoma.

Authors: Toshimitsu, H  Yoshimoto, Y  Augustine, CK  Padussis, JC  Yoo, JS  Angelica Selim, M  Pruitt, SK  Friedman, HS  Ali-Osman, F  Tyler, DS 
Citation: Toshimitsu H, etal., Ann Surg Oncol. 2010 Feb 24.
RGD ID: 2316960
Pubmed: PMID:20182810   (View Abstract at PubMed)
DOI: DOI:10.1245/s10434-010-0971-x   (Journal Full-text)

BACKGROUND: Poly(ADP-ribose) polymerase (PARP) is an important regulator of programmed cell death in response to alkylating agents such as temozolomide (TMZ). The goal of this study was to determine if a systemically administered PARP-inhibitor (INO-1001) could augment the efficacy of TMZ in a rat model of extremity malignant melanoma. MATERIALS AND METHODS: PARP activity was measured in vitro across a panel of 5 human malignant melanoma-derived cell lines. To evaluate tumor response to PARP inhibition in combination with regional isolated limb infusion (ILI) therapy with TMZ, two TMZ-resistant malignant melanoma cell lines were grown as xenografts in the hind limb of rats. INO-1001 (400 mg/kg) was injected intraperitoneally 7 times every 8 hours prior to ILI. Tumor volume was measured for up to 40 days. RESULTS: In vitro inhibition of PARP activity by INO-1001 ranged from 25.5% to 65.6%. In a mismatch repair (MMR)-deficient xenograft, treatment with INO-1001 prior to ILI significantly (P < .04) increased the efficacy of TMZ. The increase in tumor volume at day 40 following TMZ-ILI with INO-1001 was only 22.6% compared with 322.8% with TMZ-ILI alone. In a xenograft that was MMR-proficient and had high levels of O(6)-methylguanine-DNA methyltransferase (MGMT) activity, there was little improvement in TMZ efficacy with INO-1001 treatment. CONCLUSION: The PARP-inhibitor, INO-1001, can enhance the response of TMZ-resistant, MMR-deficient, malignant melanoma xenografts to intra-arterially administered TMZ in a regional treatment model of advanced extremity malignant melanoma.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
melanoma  ISOMgmt (Rattus norvegicus)2316960; 2316960protein:increased activity:skin tumor (rat)RGD 
melanoma  IEP 2316960protein:increased activity:skin tumor (rat)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Mgmt  (O-6-methylguanine-DNA methyltransferase)

Genes (Mus musculus)
Mgmt  (O-6-methylguanine-DNA methyltransferase)

Genes (Homo sapiens)
MGMT  (O-6-methylguanine-DNA methyltransferase)


Additional Information